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Background: The risk of Kaposi sarcoma (KS) among HIV-infected
persons on antiretroviral therapy (ART) is not well deﬁned in resource-
limited settings. We studied KS incidence rates and associated risk
factors in children and adults on ART in Southern Africa.
Methods: We included patient data of 6 ART programs in
Botswana, South Africa, Zambia, and Zimbabwe. We estimated
KS incidence rates in patients on ART measuring time from 30 days
after ART initiation to KS diagnosis, last follow-up visit, or death.
We assessed risk factors (age, sex, calendar year, WHO stage,
tuberculosis, and CD4 counts) using Cox models.
Findings: We analyzed data from 173,245 patients (61% female, 8%
children aged ,16 years) who started ART between 2004 and 2010.
Five hundred and sixty-four incident cases were diagnosed during
343,927 person-years (pys). The overall KS incidence rate was 164/
100,000 pys [95% conﬁdence interval (CI): 151 to 178]. The incidence
rate was highest 30–90 days after ART initiation (413/100,000 pys;
95% CI: 342 to 497) and declined thereafter [86/100,000 pys
(95% CI: 71 to 105),.2 years after ART initiation]. Male sex [adjusted
hazard ratio (HR): 1.34; 95% CI: 1.12 to 1.61], low current CD4 counts
($500 versus ,50 cells/mL, adjusted HR: 0.36; 95% CI: 0.23 to 0.55),
and age (5–9 years versus 30–39 years, adjusted HR: 0.20; 95%
CI: 0.05 to 0.79) were relevant risk factors for developing KS.
Interpretation: Despite ART, KS risk in HIV-infected persons in
Southern Africa remains high. Early HIV testing and maintaining
high CD4 counts is needed to further reduce KS-related morbidity
and mortality.
Key Words: Kaposi sarcoma, incidence rate, HIV, AIDS, antiretro-
viral therapy, cohort study
(J Acquir Immune Deﬁc Syndr 2014;67:547–554)
INTRODUCTION
Kaposi sarcoma (KS) is the most common cancer in
HIV-infected persons in Southern Africa. KS is caused by
human herpesvirus 8 (HHV-8), which is very common in
Southern Africa; 35%–50% of HIV-infected persons living in
this region are coinfected with HHV-8.1,2 HIV infection is one
of the main risk factors for developing KS and affects
between 10%–25% of the general population in Southern
African countries.3 KS incidence rate in HIV-infected persons
can be reduced by 70%–90% if the HIV infection is treated
with antiretroviral therapy (ART).4–6
Since 2004, ART has become widely available in most
Southern African countries,7 and hopes have arisen that the
KS burden would decrease. Three studies conducted in Africa
found KS incidence rates between 138/100,000 and 340/
100,000 person-years (pys) in patients treated with ART.5,8,9
These estimates suggest that the risk for developing KS in
patients on ART is still substantial. To effectively plan and
implement measures to reduce the KS burden in Africa, more
reliable information on the KS risk in patients on ART and
associated risk factors is needed.
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Our goals were to estimate the incidence rate of KS in
HIV-infected children and adults on ART in Southern Africa
within the framework of the International epidemiological
Databases to Evaluate AIDS (IeDEA) and to identify risk
factors associated with KS development in these patients.
METHODS
The International Epidemiological Databases
to Evaluate AIDS
IeDEA is a global research consortium established in
2005 with 7 regional networks (including 4 networks in sub-
Saharan Africa) that collect clinical and epidemiological data
on HIV-infected people. The African networks of IeDEA
have been described in detail elsewhere.10 The Southern
African region of IeDEA-SA includes ART programs in 7
countries (Botswana, Malawi, Lesotho, Republic of South
Africa, Zambia, Mozambique, and Zimbabwe). All cohorts
have been approved by local ethics committees or institu-
tional review boards, use standardized methods of data col-
lection, and schedule follow-up visits at least once every 6
months. Data are collected on patient demographics, use of
ART, CD4 cell counts, AIDS-deﬁning events and other com-
plications, and deaths (see www.iedea-sa.org). Cohorts trans-
fer their data to coordinating centers at the School of Public
Health and Family Medicine, University of Cape Town,
South Africa, and the Institute of Social and Preventive Med-
icine, University of Bern, Switzerland.
Inclusion Criteria and Definitions
We included data from cohorts in IeDEA-SA, which
systematically recorded KS episodes in children and adults as
part of routine clinical care. We included all ART-naive HIV-
1–infected patients who started treatment between 2004 and
2010 (ART had become more widely available in Southern
Africa from 2004 on). Data were merged on February 28,
2011. We excluded patients who had been diagnosed with
KS before or within 1 month after they began ART (consid-
ered as prevalent KS cases) and all patients who were not
followed up for at least 30 days. CD4 cell count at ART
initiation was deﬁned as CD4 cell count closest to ART ini-
tiation (between 180 days before until 30 days after). We
deﬁned ART as a regimen of at least 3 antiretroviral drugs
from any drug class, including protease inhibitors, nucleoside
reverse transcriptase inhibitors, and non-nucleoside reverse
transcriptase inhibitors.
Statistical Analysis
We calculated incidence rates by dividing the number
of patients who developed KS by the number of person-years
at risk. We measured time from 30 days after ART initiation
until the date of KS diagnosis, the last follow-up visit, or
death. We used an intent-to-continue treatment approach not
accounting for subsequent treatment changes, treatment
interruptions, or terminations. We present KS incidence rates
for the entire period of observation and for different periods
after starting ART, that is, 30–90 days, .3–6 months, .6–12
months, .1–2 years, and .2 years after ART initiation. We
assessed the following risk factors for developing KS: age,
sex, CD4 cell counts at ART initiation, current CD4 cell
counts, current or past tuberculosis (TB), and WHO clinical
stages I/II versus stages III/IV. In a sensitivity analysis, we
evaluated WHO clinical stages I–III versus stage IV. Risk
factors for incident KS were estimated using crude and
adjusted Cox proportional hazard models. The multivariable
models included sex, age, calendar period, WHO clinical
stage at ART initiation, and current CD4 cell counts. The
selection of the included variables was not automated but
based on biological and epidemiological rationale. Children
below the age of 5 years were excluded from univariable and
multivariable analyses that used absolute CD4 cell counts
because CD4 cell percentages are recommended for that age
group instead. To assess potential selection bias, we con-
ducted 2 sensitivity analyses with varying deﬁnitions of inci-
dent KS and re-examined the impact of CD4 cell counts at the
time of ART initiation on the risk for developing KS. In 1
sensitivity analysis, we included all KS cases diagnosed after
ART initiation as incident KS; in a second sensitivity analy-
sis, we excluded all patients diagnosed with KS within the
ﬁrst 6 months after ART initiation as prevalent KS cases. We
also assessed whether time spent on ART (1–6 months versus
.6 months after ART initiation) affected the risk factors for
developing KS. Interaction was assessed using likelihood
ratio tests. Results are presented as medians with interquartile
ranges (IQR), incidence rates per 100,000 pys, Kaplan–Meier
estimates of the cumulative incidence rate of KS, and crude
and adjusted hazard ratios (HR) with 95% conﬁdence inter-
vals (95% CIs). All analyses were performed in MySQL
(Community Server, GPL, version 5.5.11) and R (version
2.13.1; The R Foundation for Statistical Computing).
RESULTS
Characteristics of Cohorts and Patients
Of 22 cohorts in the IeDEA-SA database, 16 cohorts
with 141,423 patients did not systematically record KS
episodes and were therefore excluded from the analysis.
Another 19,519 patients were excluded for reasons
detailed in Figure S1 (see Supplemental Digital Content,
http://links.lww.com/QAI/A572).
We included data from 173,245 patients (52%) with
564 incident KS cases drawn from 6 cohorts located in 4
countries (Botswana, South Africa, Zambia, and Zimbabwe).
Eighty-seven percent of patients (150,732) were drawn from
the Centre for Infectious Disease Research in Zambia
(CIDRZ) cohort. The median age at ART initiation was 34
years (IQR: 28–41), and most patients were female (105,787;
61%). Median CD4 cell count at ART initiation was 142 cells
per microliter (IQR: 72–218).
Those we excluded had similar proportions of women
and girls (60% versus 61%) and a similar age distribution
(median age: both 34 years) as those we included but were
more likely to be in WHO clinical stage IV at ART initiation
(29% versus 9%). We excluded a total of 2684 KS cases from
our analysis; 2521 (94%) because they were prevalent cases.
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Overall, 564 patients developed KS and 172,681
patients did not. Median age at ART initiation was similar
in patients who did and did not develop KS (median age: 35
versus 34 years). Patients with KS had lower median CD4 cell
counts at ART initiation than patients who did not develop
KS (126 versus 142 cells/mL). Median follow-up time for all
included patients was 582 days (IQR: 241–1115 days). In
individuals who developed incident KS, median time from
ART initiation to diagnosis with KS was 229 days (IQR:
74–550 days). In patients aged $5 years, CD4 cell counts
at ART initiation were missing for 24,269 individuals (15%)
who did not develop KS and 105 individuals (19%) who
developed KS. Patients with missing CD4 cell counts at
ART initiation were slightly more likely to be in WHO clin-
ical stage III/IV at ART start than patients for whom CD4 cell
counts at ART start were available (69% versus 60%).
Incidence Rates and Risk Factors for
Developing KS
Table 1 shows the number of KS cases, person-years
under observation, and incidence rates. Overall, the incidence
rate for KS in patients on ART was 164/100,000 pys (95%
CI: 151 to 178). The KS incidence rate was 413/100,000 pys
(95% CI: 342 to 497) 30–90 days after ART start, decreased
to 188/100,000 pys (95% CI: 157 to 225) 6–12 months after
ART initiation, and reached 86/100,000 pys (95% CI: 71 to
105).2 years after ART start (Fig. 1). After 5 years on ART,
the cumulative incidence of KS was 0.5% (95% CI: 0.43 to
0.58) in women and 0.71% (95% CI: 0.62 to 0.83) in men. KS
incidence rate was lower in Zimbabwe than in Botswana,
South Africa, and Zambia. However, CIs overlapped widely.
KS incidence rate increased steeply with age in children and
young adults, reached a plateau around age 30, and increased
after age 60 (Fig. 2). KS incidence rate was 59/100,000 pys in
HIV-infected children and adolescents (aged ,16 years) and
173/100,000 pys in HIV-infected adults (aged $16 years).
In univariable analyses, the risk for developing KS
increased with age and with decreasing current CD4 cell
counts (Table 1). Men were more likely than women to
develop KS. Patients starting ART in WHO clinical stage
III/IV did not have a higher risk for developing KS than
patients starting ART in WHO clinical stage I/II. A sensitivity
analysis showed that patients who started ART at WHO stage
IV were signiﬁcantly more likely to develop KS than patients
starting ART at earlier WHO stages [HR: 2.48; 95% CI: 2.00
to 3.08]. We found no evidence for an association between
current or past TB and the risk for developing KS (data not
shown). CD4 cell counts at ART initiation were not clearly
associated with the risk for developing KS. In patients who
started ART at CD4 cell counts ,350 cells per microliter, the
risk for developing KS decreased with increasing CD4 cell
counts at ART initiation (200–349 versus ,50 cells/mL; HR:
0.64; 95% CI: 0.47 to 0.87). In contrast, in patients with CD4
cell counts $350 cells per microliter at ART initiation, KS
risk was higher than in patients with CD4 cell counts ,50
cells per microliter at ART initiation (HR: 1.28; 95% CI: 0.86
to 1.89). This ﬁnding was conﬁrmed when we included preva-
lent KS cases and also when we excluded all persons diagnosed
with KS within the ﬁrst 6 months after ART initiation for the
purpose of sensitivity analyses.
In multivariable analyses adjusted for age, sex, current
CD4 cell counts, WHO clinical stage at ART initiation, and
the calendar year, we conﬁrmed adulthood, male sex, and low
current CD4 cell counts as independent risk factors for
developing KS (Table 2). In patients with current CD4 cell
counts $500 cells per microliter, the risk for developing KS
was reduced by 64% compared with patients with current
CD4 cell counts ,50 cells per microliter (HR: 0.36; 95%
CI: 0.23 to 0.55). KS incidence rate increased with the cal-
endar year of ART initiation. Patients who started ART
between 2007 and 2010 were more likely to be diagnosed
with KS than patients who started ART between 2004 and
2006 (adjusted HR: 1.50; 95% CI: 1.23 to 1.83). This ﬁnding
was not explained by more severe immunosuppression in
patients who started ART between 2007 and 2010. In con-
trast, patients who started ART in earlier years had a lower
median CD4 cell count at ART initiation than patients who
started between 2007 and 2010: 117 cells per microliter (IQR:
55–188) versus 154 cells per microliter (IQR: 81–232). Patients
who started ART in earlier years were also more likely to present
with WHO clinical stage IV than patients who started between
2007 and 2010 (13% versus 7%). WHO stage at ART initiation
was the only risk factor that showed a signiﬁcant interaction with
time on ART (1–6 months versus .6 months after ART initia-
tion). In the multivariable analysis, the overall HR for WHO
stage III/IV versus I/II at ART initiation was 1.10, not reaching
conventional levels of statistical signiﬁcance. However, during
the ﬁrst 6 months of treatment, the adjusted HR was 1.52 (95%
CI: 1.11 to 2.08) and 0.90 (95% CI: 0.71 to 1.14) thereafter;
P-value for interaction was 0.023.
DISCUSSION
The incidence rate of KS in HIV-infected patients
treated with ART remains high (164/100,000 pys). KS
incidence rate was 413/100,000 pys 30–90 days after ART
initiation and decreased to 86/100,000 pys .2 years after
ART initiation. Low current CD4 cell counts increased the
risk for developing KS. Adults were more likely to develop
KS than children, and men were more likely to develop KS
than women.
This is one of the ﬁrst reports to describe KS incidence
rates in patients on ART in an African setting, and it is, to our
knowledge, the ﬁrst study to report KS incidence rates in
HIV-infected African children on ART. We included more
than 170,000 children and adults from 4 Southern African
countries. The multicohort design of the study allowed us to
evaluate prospectively collected information on KS cases and
patient visits. Opportunistic infections and CD4 cell counts
were reported regularly. CD4 cell count measurements at
ART initiation were available for 85% of included patients,
and WHO stages at ART start were recorded for 96% of the
included participants.
However, our study was limited because we included
only 6 of the 22 cohorts that participate in IeDEA-SA, and
87% of patients we included were drawn from the CIDRZ
cohort in Zambia. Our ﬁndings are, therefore, mainly
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representative for Zambia, and to a lesser extent for Southern
Africa as a region. Only cohorts in South Africa and
Botswana collect HIV viral loads routinely. Therefore, we
could not include HIV viral loads in our models. Because
HHV-8 serology is generally not available, we could not
assess the risk for developing KS among coinfected patients.
In addition, KS is often only clinically diagnosed and not
histologically conﬁrmed. This might have led to misclassiﬁ-
cation of KS cases and consecutively an underestimation or
overestimation of the KS incidence rate in our cohorts.
The incidence rate we estimated (in adult patients 173/
100,000 pys) is not far from incidence rates observed in adult
HIV-infected patients on ART in Uganda (201/100,000 pys),
Kenya (270/100,000 pys),8 and Switzerland (130/100,000 pys)11
(Table 3). Fink et al20 reported a substantially higher KS inci-
dence rate (450/100,000 pys [95% CI: 320 to 620]) in patients
on ART in Central and South America, which might be ex-
plained by different deﬁnitions of incident KS cases. Fink et al
included all KS cases that were diagnosed after ART initiation,
whereas we excluded KS cases that were diagnosed within the
TABLE 1. KS Incidence Rates and Unadjusted Hazard Ratios for Developing KS in Patients on ART
Patients (N) Person-Years at Risk KS Cases (N)
Incidence Rate per 100,000
pys (95% CI) HR (95% CI)
All 173,245 343,927 564 164 (151 to 178) —
Country
Botswana 704 1490 2 134 (34 to 537) —
South Africa 19,532 34,717 48 138 (104 to 183) —
Zambia 150,732 302,543 510 169 (155 to 184) —
Zimbabwe 2277 5177 4 77 (29 to 206) —
Sex
Female 105,787 213,306 296 139 (124 to 156) 1.00
Male 67,457 130,616 268 205 (182 to 231) 1.45 (1.23 to 1.72)
Age at ART start (yrs)
,5 6290 11,329 3 26 (9 to 82) 0.15 (0.05 to 0.45)
5–9 3758 8712 3 34 (11 to 107) 0.20 (0.06 to 0.62)
10–15 3201 7099 10 141 (76 to 262) 0.80 (0.43 to 1.51)
16–29 41,591 76,325 114 149 (124 to 179) 0.80 (0.64 to 0.99)
30–39 70,454 141,599 257 181 (161 to 205) 1.00
40–49 34,174 71,570 130 182 (153 to 216) 1.01 (0.82 to 1.25)
50–59 10,758 21,941 33 150 (107 to 212) 0.83 (0.58 to 1.19)
$60 3017 5349 14 262 (155 to 442) 1.37 (0.80 to 2.34)
Calendar year at ART start
2004–2006 54,717 177,507 192 108 (94 to 125) 1.00
2007–2010 118,528 166,420 372 224 (202 to 247) 1.49 (1.24 to 1.79)
WHO stage at ART start
I-II 64,121 117,855 182 154 (134 to 179) 1.00
III-IV 102,301 213,594 367 172 (155 to 190) 1.16 (0.97 to 1.39)
Missing 6823 12,477 15 120 (72 to 199) —
CD4 at ART start (cells/mL)*
,50 25,060 49,981 92 184 (150 to 226) 1.00
50–99 26,229 54,076 96 178 (145 to 217) 0.94 (0.71 to 1.26)
100–199 51,479 104,069 156 150 (128 to 175) 0.78 (0.60 to 1.01)
200–349 32,485 58,217 77 132 (106 to 165) 0.64 (0.47 to 0.87)
350–499 4511 8439 21 249 (162 to 382) 1.23 (0.76 to 1.98)
$500 2815 5046 14 277 (164 to 468) 1.36 (0.77 to 2.38)
Missing 24,374 52,767 105 199 (164 to 241) —
Current CD4 (cells/mL)*
,50 — 16,636 67 403 (317 to 512) 1.00
50–99 — 21,629 66 305 (240 to 388) 0.81 (0.57 to 1.14)
100–199 — 62,296 136 218 (185 to 258) 0.65 (0.48 to 0.87)
200–349 — 94,036 128 136 (114 to 162) 0.49 (0.36 to 0.67)
350–499 — 59,652 75 126 (100 to 158) 0.54 (0.38 to 0.77)
$500 — 55,727 37 66 (48 to 92) 0.31 (0.20 to 0.47)
Missing — 22,619 52 230 (175 to 302) —
*Children aged ,5 years were excluded from analyses of absolute CD4 cell counts.
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ﬁrst month on ART as prevalent cases. Including all KS cases
diagnosed after ART initiation as incident cases does not take
into account potential delays in KS case ascertainment. A KS
case diagnosed a few days after ART initiation might not be
a true incident case but rather a prevalent KS case, which was
diagnosed with a lag time. It has been shown that the KS
incidence estimates decrease as the lag time accounted
for increases.14 However, to date, no standard deﬁnition
of incident KS exists and cutoffs are chosen arbitrarily with
lag times commonly ranging between 0 and 90 days.8,11,13
In this study, as in other studies, KS incidence rate was
highest within the ﬁrst 6 months after ART initiation and
declined steeply thereafter.16,19 The high KS incidence rate
observed within the ﬁrst 6 months on ART might partly be
explained not only by prevalent cases that have been mis-
classiﬁed as incident cases but also by unmasking immune
reconstitution inﬂammatory syndrome.21 Once HIV-infected
patients have been on ART for more than 2 years, KS inci-
dence was relatively low (86/100,000 pys). Of note, this
relatively low incidence rate is still higher than the age stan-
dardized incidence rates of the most common cancers in the
general populations of Zambia, Zimbabwe, South Africa,
and Botswana combined, as estimated by GLOBOCAN
2012 (prostate cancer: 56.3/100,000 pys, cervical cancer:
37.6/100,000 pys).22
Interestingly, we found that KS incidence rates
increased with the calendar year. We could not ﬁnd
a biological explanation for this unexpected trend and
hypothesize that it is caused by more accurate and intensive
diagnosing and reporting in more recent years. Estimated KS
incidence rates in Zambia, Botswana, and South Africa were
similar, whereas the incidence rate in Zimbabwe was lower.
The lower incidence rate could reﬂect the lower HHV-8
seroprevalence of 35% reported in HIV-infected persons in
Zimbabwe as compared with 50% HHV-8 seroprevalence in
Zambia and South Africa.1,2 It could also be due to differ-
ences in KS diagnosing and recording between the included
cohorts. However, the difference in the KS incidence rates
FIGURE 2. KS incidence rates by age groups, stratified for
gender.
FIGURE 1. KS incidence rates by time on ART.
TABLE 2. Risk Factors for Developing KS in Patients on ART
Adjusted Hazard Ratio (95% CI)*
Sex
Female 1.00
Male 1.34 (1.12 to 1.61)
Age at ART start (yrs)
5–9 0.20 (0.05 to 0.79)
10–15 0.74 (0.35 to 1.57)
16–29 0.87 (0.68 to 1.10)
30–39 1.00
40–49 1.02 (0.81 to 1.27)
50–59 0.85 (0.58 to 1.24)
$60 1.42 (0.81 to 2.49)
Calendar period at ART start
2004–2006 1.00
2007–2010 1.50 (1.23 to 1.83)
WHO stage at ART start
I–II 1.00
III–IV 1.10 (0.91 to 1.32)
Current CD4 (cells/mL)
,50 1.00
50–99 0.82 (0.58 to 1.16)
100–199 0.65 (0.48 to 0.88)
200–349 0.52 (0.38 to 0.71)
350–499 0.59 (0.41 to 0.84)
$500 0.36 (0.23 to 0.55)
*Adjusted for all variables listed, that is, sex, age, calendar period, WHO stage, and
current CD4 cell count. Children aged ,5 years were excluded from this analysis.
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between Zimbabwe and the other countries was not statisti-
cally signiﬁcant. We found that KS incidence rates increased
from childhood to adulthood and plateaued around age 30.
After age 60, KS incidence rate increased again, but this
increase was not statistically signiﬁcant and could be a spuri-
ous ﬁnding. An increase of KS incidence rate in older adults
would be in line with a previous study23 and could be ex-
plained by aging, which is a risk factor for developing cancer
in general and acquiring HHV-8 infection in particular;
population-based studies from Africa have shown that
HHV-8 seroprevalence increases with age.24–26 The same
trend was described in HIV-infected persons in Ghana.27
Men were at higher risk for developing KS than women,
although we found no difference in the KS incidence rate
between boys and girls. Most studies in Africa found HHV-
8 seroprevalence to be only slightly higher in men than
women.28–30 Other mechanisms such as direct and indirect
effects of sex hormones31 and sex differences in immune
response to HHV-8 infection might play a role in KS devel-
opment. We found no evidence for an association between
TB and KS, which is in line with a previous study.32
Advanced WHO clinical stage was a risk factor for develop-
ing KS in the ﬁrst 6 months after ART initiation but not
thereafter. This ﬁnding might be explained by survival bias
of those on ART for more than 6 months.
Unlike other studies,9,19 we found no clear association
between CD4 cell counts at ART initiation and KS incidence
rate. In patients with CD4 cell counts ,350 cells per micro-
liter at ART start, KS risk decreased as CD4 cell counts at
ART start increased. Surprisingly, patients who started ART
at CD4 cell counts $350 cells per microliter had a higher risk
for developing KS than patients who started ART at CD4 cell
counts ,50 cells per microliter. However, this ﬁnding may
result from selection bias. At the time of this study, patients
were eligible for ART if they presented at WHO stage IV or
with CD4 cell counts ,200 or 350 cells per microliter (de-
pending on the cohort and calendar year). Patients who started
ART at CD4 counts $350 cells per microliter must have had
AIDS symptoms to qualify for ART. The condition that made
these patients eligible for ART might also have increased
their risk for developing KS. Likewise, patients with CD4
cell counts,50 cells per microliter might have already devel-
oped KS at baseline, and thus might have been excluded as
prevalent cases. However, even when we included all preva-
lent KS cases in a sensitivity analysis, the observed pattern for
the association between CD4 cell counts at ART start and KS
incidence rates remained similar. Missing CD4 cell counts at
ART start might have also introduced a selection bias. Very
sick patients in advanced WHO clinical stages are more likely
to start ART without a CD4 cell count measurement than
patients with early stage disease. This was also the case for
our sample: patients with missing CD4 cell counts at ART
initiation were more likely to be in WHO clinical stages III/IV
than patients with available CD4 cell counts (69% versus
60%). Finally, current CD4 cell counts, which might be less
affected by selection biases, showed a clear decline in KS risk
as CD4 cells counts increased. This ﬁnding is consistent with
those of previous studies conducted in high-income18,23 and
TABLE 3. KS Incidence Rates in Patients on ART in Resource-Rich and Resource-Limited Regions
Authors Cohort Country Calendar Years Patients on ART KS Incidence Rate per 100, 000 pys
Resource-rich regions N Children Adults
Ledergerber et al12 SHCS Switzerland 1995–1999 2410 NR 140
Clifford et al13 SHCS Switzerland 1985–2003 NR NR 109
Franceschi et al11 SHCS Switzerland 1984–2006 NR NR 130
Suarez-Garcia et al14 CoRIS/CoRIS-MD Spain 1997–2008 NR NR 199
Carrieri et al15 DMI-2 France 1996–2001 2589 NR 122
Lacombe et al16 FHDH-ANRS CO4 France, French overseas territories 1992–2009 40,083 NR 137
Mocroft et al17 EuroSIDA Europe, Israel 1994–1999 NR NR 700
Lodi et al18,* CASCADE Europe, Australia, Canada 1986–2006 4199 NR 358
Yanik et al19 CNICS United States 1996–2011 11,485 NR 304
Resource-limited
regions
Fink et al20 CCASAnet/IeDEA Caribbean, Central and
South America
2007–2009 3372 NR 450
Asiimwe et al9 HBAC Uganda 2003–2008 1121 NR 340
Martin et al8 IeDEA Uganda 2008–2011 NR NR 201
Martin et al8 IeDEA Kenya 2008–2011 NR NR 270
Current study IeDEA Southern Africa 2004–2010 173,245 59 173
Estimates from different studies are adjusted for different variables.
*Includes only men who have sex with men.
CASCADE, Concerted Action of Seroconversion to AIDS and Death in Europe; CCASAnet, Caribbean, Central and South American network for HIV research; CNICS, Centers
for AIDS Research (CFAR) network of integrated clinical systems; CoRIS/CoRIS-MD, Spanish cohorts of naive HIV-infected patients; DMI-2, longitudinal database of HIV-infected
individuals followed at Nice University Hospital, France; EuroSIDA, collection of European cohort studies; FHDH-ANRS CO4, The French Hospital Database on HIV; HBAC,
Home-Based AIDS Care program; SHCS, Swiss HIV Cohort Study; NR, not reported.
Adapted from Semeere et al.4 Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner
of the copyright in the original work and from the owner of copyright in the translation or adaptation.
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low-income settings.8 Because maintaining CD4 cell counts
$500 cells per microliter decreases the risk for developing
KS, it seems likely that starting ART at CD4 cell counts
,500 cells per microliter—as recently recommended by the
WHO33—could further reduce the incident KS burden.
Despite ART, the incidence rate of KS in HIV-infected
patients remains high and is especially high within the ﬁrst 6
months after ART initiation. The KS burden might be
further reduced by early HIV testing and maintaining high
CD4 cell counts.
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